
Catalyst Opportunity Funds Closes Fund II at $140M With Major Banking, Healthcare Limited Partners
SALT LAKE CITY--(BUSINESS WIRE)-- Catalyst Opportunity Funds (Catalyst), a double-bottom-line real estate investment platform focused on impactful investments in historically underserved U.S. markets, today announced the final close of Catalyst Opportunity Fund II LP ('Fund II') with total capital commitments of $140 million. The close brings Catalyst's total assets under management to $350 million, representing more than $1.3 billion in project costs across its portfolio.
Fund II raised capital from a base of prominent institutional investors, including JPMorganChase, UnitedHealth Group, American Express, and KeyBank, as well as foundations, family offices, and other mission-aligned capital partners. The strong investor participation underscores growing institutional demand for attractive market-rate, socially responsible real estate investment opportunities – even amid broader market fundraising challenges.
Unlike many comparable investment strategies that focus on preserving existing affordable housing through acquisition and renovations, Catalyst is expanding the nation's housing stock through ground-up development, directly addressing the estimated 5.5-million-unit shortage of new construction. By bringing new workforce and affordable housing units online, Catalyst targets the root cause of the supply-demand imbalance that has exacerbated housing affordability challenges nationwide.
Fund II is primarily focused on investing in workforce and affordable housing developments that serve households earning 60-80% of area median income (AMI) – a segment often referred to as 'the missing middle.' This group includes working families and individuals who earn too much to qualify for traditional affordable housing subsidies, but still struggle with rising housing costs in high-growth markets. In addition to housing, Fund II also invests in mixed-use developments and commercial spaces that provide essential services, further strengthening the economic and social fabric of these communities.
'The successful close of Fund II demonstrates that institutional investors continue to see value in well-executed impact investment strategies,' said Jeremy Keele, Co-Founder and Managing Partner at Catalyst Opportunity Funds. 'We are grateful for the confidence of our new and returning partners, and we remain committed to deploying this capital into transformative real estate projects that create lasting financial and social benefits in the neighborhoods we serve.'
Fund II has already been deployed into eight real estate investments across strategic U.S. markets. Three of these developments – Metropolitan Village, The Eden, and The Moraine – are now operational and delivering impact in the regions they serve. Metropolitan Village was honored with the 2024 CoStar Impact Award for Multifamily Development of the Year in Greensboro and Winston-Salem, North Carolina, and The Moraine was recently recognized with CoStar's 2025 Impact Award as Multifamily Development of the Year in Seattle. These awards underscore Catalyst's commitment to expanding access to high-quality housing in underserved communities.
Catalyst's investment strategy prioritizes data-driven, locally responsive development, with first-floor commercial spaces in many projects dedicated to essential businesses and service-oriented tenants, creating a "housing-plus" model that enhances economic and social stability for residents. The firm also prioritizes working with local developers, helping to keep investment within the community while supporting greater opportunity. Together, this approach advances strong market-rate performance, long-term investor outcomes, and measurable social benefits.
Investor Perspectives on Fund II
'Investing in workforce housing is critical to addressing the widening housing affordability gap across the country,' said Diana Kolar Leach, Executive Director – Head of Fund Investing, Impact Finance & Advisory at JPMorganChase. 'Catalyst's community-first approach aligns with our commitment to supporting scalable solutions that not only expand access to quality housing but also invest in commercial spaces that strengthen communities and drive long-term economic resilience, all while delivering strong financial outcomes.'
'Access to stable, quality housing is a critical social driver of health,' said Courtney Mattson, Vice President, Assistant Treasurer at UnitedHealth Group. 'At UnitedHealth Group, we recognize the deep connection between housing and health outcomes. This investment expands access to affordable housing while fostering healthier communities – ensuring individuals and families have the stability needed for improved well-being and financial security.'
'Catalyst's mission to expand the supply of affordable housing and activate commercial spaces for underserved communities aligns with our goal of investing capital to help families and businesses in underserved communities thrive,' said Celia Smoot, Senior Vice President at KeyBank. 'Affordable housing is a cornerstone of economic opportunity, and everyone deserves to live and work in a community that supports their aspirations.'
About Catalyst:
Catalyst is a double bottom-line private equity firm focused on transformative real estate investments in high potential, but historically underserved U.S. markets. With over $1.3B worth of total real estate across the U.S., Catalyst invests in impactful, market-rate-return-oriented development projects led by community-driven developers, with a primary focus on workforce affordable housing. In addition to providing new, affordable housing units, Catalyst works to facilitate an influx of community services tailored to the needs of each investment community, including preventative healthcare, workforce training, and healthy, nutritious food. Institutional investment expertise, relationships with qualified sponsors in high-growth secondary markets, as well as significant experience in the structuring of creative capital stacks give Catalyst a competitive advantage in delivering long-term value creation to investors, as well as positive outcomes within communities. For more information, please visit www.catalystimpact.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
IDEXX Laboratories (NasdaqGS:IDXX) Launches Catalyst Cortisol Test for Canine Health
IDEXX Laboratories recently introduced its Catalyst® Cortisol Test, an advance in veterinary diagnostics, and reported an earnings growth with a raised revenue guidance for 2025. Furthermore, the company repurchased 930,800 shares, indicating strong financial health. These developments likely supported IDEXX's 22% share price increase over the last quarter. Meanwhile, broader market movements were relatively modest, with indices experiencing slight gains amid optimistic trade discussions between the U.S. and China and positive economic data. IDEXX's performance was possibly bolstered by its innovative launches and solid financials, in line with buoyant market sentiments. We've spotted 1 risk for IDEXX Laboratories you should be aware of. Find companies with promising cash flow potential yet trading below their fair value. The introduction of the Catalyst® Cortisol Test and share repurchase strengthens IDEXX Laboratories' position in veterinary diagnostics, potentially boosting revenue and earnings forecasts through increased diagnostic usage and market expansion. Over the past five years, IDEXX's total shareholder returns increased by 63.06%, including price movements and dividends, reflecting consistent long-term growth despite some market volatilities. In contrast, IDEXX underperformed the US Medical Equipment industry over the past year, which returned 9%. Though the current share price increase in the last quarter aligns with recent innovations and improved guidance, it trades close to the consensus price target of US$496.54. This suggests analysts view the company as nearing fair value. However, continued product innovations and strategic international expansions might influence future market valuations as IDEXX strives to enhance revenue and earnings growth amid potential challenges such as trade tensions and changing clinical visits. Our comprehensive valuation report raises the possibility that IDEXX Laboratories is priced higher than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:IDXX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ...
Release Date: May 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Corcept Therapeutics Inc (NASDAQ:CORT) reported a revenue increase to $157.2 million in Q1 2025, up from $146.8 million in the same quarter last year. The company is confident in its future growth prospects, with a significant increase in the prescriber base and patient growth for hypercortisolism treatments. Corcept Therapeutics Inc (NASDAQ:CORT) has expanded its sales force significantly, from 60 to 125 clinical specialists, with plans to reach 175 by year-end. The company's Catalyst study showed that 1 in 4 patients with difficult-to-control diabetes have hypercortisolism, highlighting a significant market opportunity. Corcept Therapeutics Inc (NASDAQ:CORT) is advancing its oncology portfolio, with positive results from the Rosella trial in platinum-resistant ovarian cancer, showing a 30% reduction in disease progression risk. Net income decreased to $20.5 million in Q1 2025 from $27.8 million in the same quarter last year. The company faced operational challenges with its pharmacy vendor, affecting Q1 results due to insufficient capacity to handle increased prescription volumes. A transition to authorized generic tablets, which have a lower net price, led to a 13% decrease in average price per tablet. Corcept Therapeutics Inc (NASDAQ:CORT) is involved in ongoing patent litigation with TEA, which could impact future market dynamics. The company's ALS trial did not meet its primary endpoint, although there was an observed improvement in overall survival, indicating potential regulatory challenges. Warning! GuruFocus has detected 7 Warning Signs with CORT. Q: Can you explain where Relacorilant fits into the treatment paradigm for ovarian cancer, and how it compares to other treatments like Elaheir? A: Roberto Viera, President of the Oncology Division, explained that Relacorilant is poised to become a new standard of care in platinum-resistant ovarian cancer. The treatment landscape is fragmented, and Relacorilant offers a new option in multiple lines of therapy, including before or after biomarker-driven agents like Elaheir. Q: With the improvements in March and April, how will this affect revenue projections for the upcoming quarters? A: Sean Maduk, President of the Endocrinology Division, stated that the fundamentals of the business are strong, and growth is expected to continue and accelerate throughout the year. The company is confident in achieving its revenue guidance of $900 to $950 million. Q: What is the mix between branded and authorized generic business for Korlym, and how does it affect revenue projections? A: Sean Maduk noted that over half of the product is currently on the authorized generic, and this percentage is expected to increase. Future volume growth is expected to outweigh any price changes due to the mix of products. Q: Are you expecting an advisory committee meeting for Relacorilant's NDA? A: Charlie Robb, Chief Business Officer, stated that they do not expect an advisory committee meeting, as it was not required for Korlym or other recently approved drugs in hypercortisolism. Q: What corrective measures did the pharmacy vendor take to improve operations, and can they meet future demand? A: Sean Maduk explained that the pharmacy vendor addressed staffing issues that led to prescription delays. The vendor has since improved operations, and the company is exploring broader distribution networks for future products like Relacorilant. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
29-05-2025
- Yahoo
Koppers Names James A. Sullivan President and Chief Transformation Officer; New Role Created to Oversee Company-wide Catalyst Initiative
PITTSBURGH, May 29, 2025 /PRNewswire/ -- Koppers Holdings Inc. (NYSE: KOP), a leading integrated global provider of treated wood products, wood treatment chemicals, and carbon compounds, today announced the appointment of James A. Sullivan as President and Chief Transformation Officer, effective June 1, 2025. In this newly created role, Sullivan will lead the Koppers enterprise-wide transformation process named Catalyst. He will oversee the evaluation, scoping, quantification, planning and execution of hundreds of opportunities through a rigorous process aimed at maximizing performance across every dimension of the company. Sullivan will continue to report to Chief Executive Officer and Chairman of the Board Leroy Ball; business unit leadership will now also report to Ball in order to enable Sullivan to devote his full and focused attention to driving change. "While the changes undertaken by Koppers over the past decade have certainly been transformational, I believe we still have a tremendous opportunity to dramatically improve our margin and cash flow profile," said Leroy Ball. "This organizational change will allow Jim to intensely focus on implementing those actions that give us the best opportunity for success. His leadership of Catalyst is expected to build the bridge connecting our current strategy to our 2030 strategy." Sullivan will lead the newly established Transformation Office, a cross-functional team responsible for coordinating and executing the company's Catalyst Initiative, an enterprise-wide transformation process designed to challenge the status quo and change the way the company approaches performance improvements across all facets of the organization. "I'm very excited to step into this role at such a critical time for Koppers," said Jim Sullivan. "I look forward to working with our talented teams around the world to unlock new opportunities and build a stronger, more resilient company." Sullivan has more than 25 years of industry experience and more than a decade of executive leadership experience at Koppers, joining the company in June 2013. He most recently served as President and Chief Operating Officer, where he played a significant role in the development of the company's strategy. About Koppers Koppers (NYSE: KOP) is an integrated global provider of essential treated wood products, wood preservation technologies and carbon compounds. Our team of 2,100 employees create, protect and preserve key elements of our global infrastructure – including railroad crossties, utility poles, outdoor wooden structures, and production feedstocks for steel, aluminum and construction materials, among others – applying decades of industry-leading expertise while constantly innovating to anticipate the needs of tomorrow. Together we are providing safe and sustainable solutions to enable rail transportation, keep power flowing, and create spaces of enjoyment for people everywhere. Protecting What Matters, Preserving The Future. Learn more at Inquiries from the media should be directed to Ms. Jessica Franklin Black at BlackJF@ or 412-227-2025. Inquiries from the investment community should be directed to Ms. Quynh McGuire at McGuireQT@ or 412-227-2049. Safe Harbor Statement Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may include, but are not limited to, statements about sales levels, acquisitions, restructuring, declines in the value of Koppers assets and the effect of any resulting impairment charges, profitability and anticipated expenses and cash outflows. All forward-looking statements involve risks and uncertainties. All statements contained herein that are not clearly historical in nature are forward-looking, and words such as "outlook," "guidance," "forecast," "believe," "anticipate," "expect," "estimate," "may," "will," "should," "continue," "plan," "potential," "intend," "likely," or other similar words or phrases are generally intended to identify forward-looking statements. Any forward-looking statement contained herein, in other press releases, written statements or other documents filed with the Securities and Exchange Commission, or in Koppers communications and discussions with investors and analysts in the normal course of business through meetings, phone calls and conference calls, regarding future dividends, expectations with respect to sales, earnings, cash flows, operating efficiencies, restructurings, cost reduction efforts, product introduction or expansion, the benefits of acquisitions, divestitures, joint ventures or other matters as well as financings and debt reduction, are subject to known and unknown risks, uncertainties and contingencies. Many of these risks, uncertainties and contingencies are beyond our control, and may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. Factors that might affect such forward-looking statements include, among other things, availability of and fluctuations in the prices of key raw materials, including coal tar, lumber and scrap copper; the impact of changes in commodity prices, such as oil, copper and chemicals, on product margins; the extent of the dependence of certain of our businesses on certain market sectors and customers; economic, political and environmental conditions in international markets, including governmental changes, tariffs, restrictions on trade and restrictions on the ability to transfer capital across countries; general economic and business conditions; potential difficulties in protecting our intellectual property; the ratings on our debt and our ability to repay or refinance our outstanding indebtedness as it matures; our ability to operate within the limitations of our debt covenants; unexpected business disruptions; potential delays in timing or changes to expected benefits from cost reduction efforts; potential impairment of our goodwill and/or long-lived assets; demand for Koppers goods and services; competitive conditions; capital market conditions, including interest rates, borrowing costs and foreign currency rate fluctuations; disruptions and inefficiencies in the supply chain; changes in laws; the impact of environmental laws and regulations; unfavorable resolution of claims against us, as well as those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by Koppers, particularly our latest annual report on Form 10-K and any subsequent filings by Koppers with the Securities and Exchange Commission. Any forward-looking statements in this release speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after that date or to reflect the occurrence of unanticipated events. For Information: Quynh McGuire, Vice President, Investor Relations412 227 2049McGuireQT@ View original content to download multimedia: SOURCE KOPPERS HOLDINGS INC. Sign in to access your portfolio